Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study. In the ...

Heart failure causes vary, but the result is a weakened heart that's limited in its capacity to meet your body's need for oxygen and nutrients delivered in the blood supply. This is due to loss of ...

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with ... their study drug treatment, which reduces the ...

Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of its technology has been shown in a new AstraZeneca-partnered candidate for heart ...

In general, rhythm control is more effective at reducing symptoms, improving quality of life, and preventing progression of atrial fibrillation and development of related complications like heart ...

Atrial fibrillation (AF) and chronic heart failure (CHF) are two major and even growing cardiovascular conditions that often coexist. However, few data are available to guide treatment of AF in ...

Participants with insufficient hearing, poor hearing, or hearing aid use had higher heart failure risks compared with those with normal hearing. HealthDay News — Poor hearing is associated with an ...

Hearts damaged through cardiac disease can repair themselves with the help of a class of drugs called ... tissue within the heart (which increases the risk of heart failure because it prevents ...

In an statement released Monday, the Vatican said Francis died of a cerebral stroke, coma and subsequent irreversible heart failure ... a further change in his drug therapy.

Heart failure is fairly common, with more than a million UK adults currently affected, many people are not aware of symptoms to look out for. Unlike its name may suggest, heart failure does not ...

Ottawa, April 23, 2025 (GLOBE NEWSWIRE) -- The pain management drugs market size is currently valued at more than $87.19 billion and is projected to reach approximately $125.68 billion by 2034.